CompletedNCT00477672
Pimavanserin or placebo for psychosis in Parkinson disease
About this title
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Read the official source — NCT00477672Medication studyAges 40+Multiple countriesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: from 40 years.
- Listed locations
- Gilbert and 77 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 298
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, United Kingdom, ...
- Age range
- Over 40 Years
- Official registry ID
- NCT00477672
- Official title
Show the full official title
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease
Get this study by email
Recruitment & locations
CompletedGilbert, United States · Phoenix, United States · Berkeley, United States
72 more locations
- Carson, United States
- Fountain Valley, United States
- Irvine, United States
- Sunnyvale, United States
- Danbury, United States
- Fairfield, United States
- Boca Raton, United States
- Gainesville, United States
- Jacksonville, United States
- Miami, United States
- Pompano Beach, United States
- Port Charlotte, United States
- Sarasota, United States
- St. Petersburg, United States
- Tampa, United States
- Augusta, United States
- Springfield, United States
- Scarborough, United States
- Worcester, United States
- Southfield, United States
- Traverse City, United States
- Toms River, United States
- Kingston, United States
- Rochester, United States
- Asheville, United States
- Salisbury, United States
- Columbus, United States
- Warwick, United States
- Brentwood, United States
- San Antonio, United States
- Richmond, United States
- Kirkland, United States
- Spokane, United States
- Pleven, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Clermont-Ferrand, France
- Marseille, France
- Nantes, France
- Pessac, France
- Strasbourg, France
- Toulouse, France
- Bangalore, India
- Hyderabad, India
- Karnataka, India
- Mangalore, India
- Mumbai, India
- New Dalhi, India
- Pune, India
- Tamil Nadu, India
- Visakhapatnam, India
- Kazan', Russia
- Kirov, Russia
- Moscow, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Smolensk, Russia
- Kharkiv, Ukraine
- Kiev, Ukraine
- Luhansk, Ukraine
- Lviv, Ukraine
- Vinnytsia, Ukraine
- Barnsley, United Kingdom
- Blackburn, United Kingdom
- Brighton, United Kingdom
- Dorset, United Kingdom
- London, United Kingdom
- Newcastle upon Tyne, United Kingdom
- North Shields, United Kingdom
- Salford, United Kingdom
- Russia
Questions about this study
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Did this study involve medication?
Yes. The study involved medication, including Pimavanserin tartrate (ACP-103) and Placebo.
Who was this study for?
Listed age limits: from 40 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia